Pulse Check: The Cardiovascular Conversations | Ep. 2 | Coronary Imaging Innovation and the Path to Targeted Therapies

Impossible d'ajouter des articles

Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.

Veuillez réessayer plus tard

Échec de l’élimination de la liste d'envies.

Veuillez réessayer plus tard

Impossible de suivre le podcast

Impossible de ne plus suivre le podcast

Pulse Check: The Cardiovascular Conversations | Ep. 2 | Coronary Imaging Innovation and the Path to Targeted Therapies

Écouter gratuitement

Voir les détails

Offres de saison | 0,99 € par mois pendant les 3 premiers mois

5,99 €/mois par la suite. Des conditions s’appliquent. Annulation mensuelle possible.

In episode two, the conversation turns to clinical development and the power of imaging biomarkers. Dr. Cheerag Shirodaria (Fortrea) and Chris Farina (Abcentra) delve into how innovations in technology and imaging, such as coronary CT angiography (CCTA) and the Fat Attenuation Index (FAI) are transforming risk stratification—reclassifying patients and identifying inflammation even in those with “normal” arteries. The episode also highlights the challenges of trial design in novel populations and the critical role of sponsor-CRO-vendor collaborations, including Fortrea’s CRO support. For pharma teams focused on precision medicine and inflammation-targeted therapies, this episode offers valuable insights into the future of cardiovascular care.

Aucun commentaire pour le moment